VIA
JAZZ icon

Vident Investment Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Vident Investment Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,142
Closed -$2.25M – 528
2023
Q2 		$2.25M Sell
18,142
-50,653
-74% -$6.82M 0.08% 285
2023
Q1 		$10.1M Buy
68,795
+48,595
+241% +$7.19M 0.33% 70
2022
Q4 		$3.22M Sell
20,200
-1,114
-5% -$163K 0.12% 197
2022
Q3 		$2.8M Sell
21,314
-5,721
-21% -$870K 0.09% 248
2022
Q2 		$4.21M Sell
27,035
-16,166
-37% -$2.49M 0.13% 196
2022
Q1 		$6.72M Sell
43,201
-15,729
-27% -$2.28M 0.18% 136
2021
Q4 		$7.51M Sell
58,930
-12,579
-18% -$1.65M 0.2% 111
2021
Q3 		$9.31M Buy
71,509
+56,013
+361% +$8.46M 0.28% 71
2021
Q2 		$2.75M Sell
15,496
-704
-4% -$122K 0.08% 272
2021
Q1 		$2.66M Sell
16,200
-1,592
-9% -$262K 0.09% 247
2020
Q4 		$2.94M Sell
17,792
-1,259
-7% -$188K 0.12% 146
2020
Q3 		$2.72M Sell
19,051
-2,204
-10% -$273K 0.14% 135
2020
Q2 		$2.35M Sell
21,255
-5,949
-22% -$658K 0.12% 159
2020
Q1 		$2.71M Buy
27,204
+22,874
+528% +$2.96M 0.18% 112
2019
Q4 		$646K Sell
4,330
-132
-3% -$18K 0.04% 484
2019
Q3 		$572K Sell
4,462
-10
-0.2% -$1.34K 0.05% 294
2019
Q2 		$638K Sell
4,472
-2,774
-38% -$373K 0.05% 253
2019
Q1 		$1.04M Buy
7,246
+2,773
+62% +$362K 0.06% 411
2018
Q4 		$554K Buy
+4,473
New +$664K 0.03% 557
2018
Q1 		– Sell
-24,636
Closed -$3.32M – 923
2017
Q4 		$3.32M Buy
24,636
+1,320
+6% +$183K 0.15% 159
2017
Q3 		$3.41M Buy
23,316
+21,477
+1,168% +$3.25M 0.18% 101
2017
Q2 		$286K Sell
1,839
-401
-18% -$61.3K 0.02% 397
2017
Q1 		$325K Buy
+2,240
New +$292K 0.03% 362
2015
Q4 		– Sell
-9,775
Closed -$1.3M – 613
2015
Q3 		$1.3M Buy
9,775
+3,246
+50% +$559K 0.18% 142
2015
Q2 		$1.15M Buy
+6,529
New +$1.17M 0.15% 181

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vident Investment Advisory's JAZZ Position: Q3 2023 in Review

Vident Investment Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 18,142 shares — an estimated $2.25M sold.

Vident Investment Advisory first reported a position in JAZZ in Q2 2015 and held it in 25 quarters. The position peaked at $10.1M in Q1 2023. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

  • Vident Investment Advisory reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 18,142 Jazz Pharmaceuticals shares in Q3 2023, an estimated $2.25M.
  • Vident Investment Advisory first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 25 quarters.
  • Vident Investment Advisory's Jazz Pharmaceuticals position peaked at $10.1M in Q1 2023.
  • 484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.